| |
| Assessment of interferon, peginterferon, tenofovir, entecavir, lamivudine and adefovir for the treatment of chronic hepatitis B in hbeag-positive patients without cirrhosis |
| Mosegui GB, Costa e Silva FV, Vianna CM, Peregrino AA, de Oliveira FS, Rodrigues MP, Oliveira NH, Jardim FN |
|
|
| |
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Mosegui GB, Costa e Silva FV, Vianna CM, Peregrino AA, de Oliveira FS, Rodrigues MP, Oliveira NH, Jardim FN. Assessment of interferon, peginterferon, tenofovir, entecavir, lamivudine and adefovir for the treatment of chronic hepatitis B in hbeag-positive patients without cirrhosis. International Journal of Pharmacy and Pharmaceutical Sciences 2013; 5(Supplement1): 208-212 Indexing Status Subject indexing assigned by CRD MeSH Adenine; Antiviral Agents; Brazil; Cost-Benefit Analysis; Guanine; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Markov Chains; Organophosphonates; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins AccessionNumber 22013017005 Date bibliographic record published 10/06/2013 |
| |
|
|
